爵士制药 JAZZ 深 沪
等待开盘 10-09 09:30:00 美东时间
223.27
-7.920
-3.43%
华盛通- 最 高229.16
- 今 开228.55
- 成交量 94.91万股
- 最 低 214.68
- 昨 收 231.19
- 总市值 144.93亿
- 52周最高 266.375
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 128.80
- 委 比 -56.64%
- 总股本 6491.46万
- 历史最高 266.375
- 量 比 1.33
- 振 幅 6.26%
- 历史最低 31.87
- 每 手 1
- 风险率 38.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286
Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $281 to $286.
10-08 00:50
Jazz Builds Real-World Case for Zanidatamab in Advanced HER2+ Gastroesophageal Cancer
Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical stud...
10-03 00:30
美股盘后 | Vicor电子大升8.33%，Nu Holdings大升6.23%
Vicor电子大升8.33%；Nu Holdings大升6.23%；富达国民金融上升3.47%
10-01 06:10
Nuvation, Jazz gain new Buys at Citi on oncology prospects
Citi launched its coverage of Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings on Wednesday as part of a broader review of the U.S. biopharma sector, highlighting the companies' on...
10-01 01:47
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, leveraging his 20+ years of biotech experience, including over $2B in oncology partnerships. Donigian will help advance Sutro’s ADC platform and pipeline, including STRO-004, STRO-006, and STRO-227, while building strategic collaborations. He previously led business development at Zymeworks and NanoString Technologies. Sutro granted Donigian stock options and...
09-29 12:00
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.
09-24 21:05
Jazz Pharmaceuticals Refinances Term Loan, Extends Maturities
An announcement from Jazz Pharmaceuticals ( ($JAZZ) ) is now available. On Sept...
09-24 04:52
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc. has completed the acquisition of Theravance Biopharma, enhancing its strategy to build a diversified biotechnology company. A conference call discussing the acquisition details will be held on September 28 at 8:30 am ET. Zymeworks combines innovative R&D with growing commercial assets, including YUPELRI® and Ziihera®, leveraging its Azymetric™ platform for next-generation antibody technologies.
09-23 20:01
